Celcuity Inc. (CELC)
NASDAQ: CELC · IEX Real-Time Price · USD
16.66
+0.73 (4.58%)
At close: Jun 24, 2024, 4:00 PM
16.27
-0.39 (-2.34%)
After-hours: Jun 24, 2024, 5:45 PM EDT

Company Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer.

It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.

The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Inc.
Celcuity logo
Country United States
Founded 2011
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Brian F. Sullivan

Contact Details

Address:
16305 36th Avenue N, Suite 100
Minneapolis, Minnesota 55446
United States
Phone 763-392-0767
Website celcuity.com

Stock Details

Ticker Symbol CELC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001603454
CUSIP Number 15102K100
ISIN Number US15102K1007
SIC Code 8071

Key Executives

Name Position
Brian F. Sullivan Co-Founder, Chairman and Chief Executive Officer
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, Vice President, Secretary and Director
Vicky Hahne Chief Financial Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of Research & Development
Sheri Smith Acting Head of Clinical Operations
Igor Gorbatchevsky M.D. Chief Medical Officer
Eldon C. Mayer III, M.B.A. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 10, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 31, 2024 8-K Current Report
May 30, 2024 424B5 Filing
May 30, 2024 8-K Current Report
May 20, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 15, 2024 10-Q Quarterly Report
May 15, 2024 8-K Current Report
May 13, 2024 8-K Current Report
Apr 25, 2024 D/A Filing
Apr 24, 2024 144 Filing